Towards standardization of the parameters for opening the blood-brain barrier with focused ultrasound to treat glioblastoma multiforme: A systematic review of the devices, animal models, and therapeutic compounds used in rodent tumor models.
blood-brain barrier
chemotherapy
focused ultrasound
glioblastoma multiforme
immunotherapy
microbubble
neuro-oncology
non-invasive
Journal
Frontiers in oncology
ISSN: 2234-943X
Titre abrégé: Front Oncol
Pays: Switzerland
ID NLM: 101568867
Informations de publication
Date de publication:
2022
2022
Historique:
received:
03
11
2022
accepted:
20
12
2022
entrez:
6
3
2023
pubmed:
7
3
2023
medline:
7
3
2023
Statut:
epublish
Résumé
Glioblastoma multiforme (GBM) is a deadly and aggressive malignant brain cancer that is highly resistant to treatments. A particular challenge of treatment is caused by the blood-brain barrier (BBB), the relatively impermeable vasculature of the brain. The BBB prevents large molecules from entering the brain parenchyma. This protective characteristic of the BBB, however, also limits the delivery of therapeutic drugs for the treatment of brain tumors. To address this limitation, focused ultrasound (FUS) has been safely utilized to create transient openings in the BBB, allowing various high molecular weight drugs access to the brain. We performed a systematic review summarizing current research on treatment of GBMs using FUS-mediated BBB openings in
Identifiants
pubmed: 36873300
doi: 10.3389/fonc.2022.1072780
pmc: PMC9978816
doi:
Types de publication
Systematic Review
Langues
eng
Pagination
1072780Informations de copyright
Copyright © 2023 Thombre, Mess, Kempski Leadingham, Kapoor, Hersh, Acord, Kaovasia, Theodore, Tyler and Manbachi.
Déclaration de conflit d'intérêts
AM teaches and consults for BK Medical GE Healthcare, Neurosonics Medical, and is an inventor on a number of patent-pending FUS technologies. BT has research funding from NIH and is a co-owner for Accelerating Combination Therapies*. Ashvattha Therapeutics Inc. has also licensed one of her patents and she is a stockholder for Peabody Pharmaceuticals. *includes equity or options. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
J Control Release. 2019 Feb 10;295:130-139
pubmed: 30537486
Ultrasound Med Biol. 2019 Oct;45(10):2758-2766
pubmed: 31378549
Clin Cancer Res. 2009 Nov 15;15(22):7092-8
pubmed: 19861433
Neurotherapeutics. 2013 Jul;10(3):459-72
pubmed: 23549647
J Acoust Soc Am. 2009 Dec;126(6):3071-83
pubmed: 20000921
Theranostics. 2017 Jan 1;7(1):144-152
pubmed: 28042323
Ultrasound Med Biol. 2003 May;29(5):739-48
pubmed: 12754073
Front Neurosci. 2019 Jul 24;13:696
pubmed: 31396029
Neurosurg Focus. 2018 Feb;44(2):E2
pubmed: 29385919
Ultrasound Med Biol. 2008 Jun;34(6):930-7
pubmed: 18294757
Front Oncol. 2020 Sep 10;10:1663
pubmed: 33014832
Expert Rev Neurother. 2015 May;15(5):477-91
pubmed: 25936845
Radiology. 2016 Oct;281(1):99-108
pubmed: 27192459
Sci Transl Med. 2016 Jun 15;8(343):343re2
pubmed: 27306666
ACS Appl Mater Interfaces. 2019 Mar 27;11(12):11144-11156
pubmed: 30883079
Curr Pharm Des. 2014;20(10):1499-509
pubmed: 23789953
Langmuir. 2014 May 20;30(19):5557-63
pubmed: 24758714
Bubble Sci Eng Technol. 2009 Nov;1(1-2):3-17
pubmed: 20574549
Sci Rep. 2020 Oct 26;10(1):18220
pubmed: 33106562
J Mol Neurosci. 2012 Mar;46(3):677-87
pubmed: 21861133
Front Oncol. 2020 Jun 05;10:739
pubmed: 32582530
Front Neurol. 2021 Nov 04;12:749047
pubmed: 34803886
J Cereb Blood Flow Metab. 2012 Nov;32(11):1959-72
pubmed: 22929442
Ultrasound Med Biol. 2012 Oct;38(10):1716-25
pubmed: 22818878
ACS Appl Mater Interfaces. 2019 Apr 24;11(16):14576-14587
pubmed: 30900870
Polymers (Basel). 2019 Apr 25;11(4):
pubmed: 31027272
Radiology. 2019 May;291(2):459-466
pubmed: 30912718
Phys Med Biol. 2015 Dec 7;60(23):9079-94
pubmed: 26562661
Neuro Oncol. 2010 Oct;12(10):1050-60
pubmed: 20663792
Cancer Chemother Pharmacol. 2016 Feb;77(2):269-80
pubmed: 26666650
Int J Mol Sci. 2021 Nov 23;22(23):
pubmed: 34884457
NeuroRx. 2005 Jan;2(1):86-98
pubmed: 15717060
Front Pharmacol. 2019 Feb 07;10:86
pubmed: 30792657
Cold Spring Harb Perspect Biol. 2015 Jan 05;7(1):a020412
pubmed: 25561720
J Adv Res. 2020 Jun 21;26:15-28
pubmed: 33133680
Nanomedicine. 2014 Jul;10(5):1075-87
pubmed: 24374363
PLoS Med. 2021 Mar 29;18(3):e1003583
pubmed: 33780438
Ultrasound Med Biol. 2014 Jan;40(1):130-7
pubmed: 24239362
Theranostics. 2019 Aug 14;9(21):6284-6299
pubmed: 31534551
Int J Nanomedicine. 2012;7:723-30
pubmed: 22359451
Radiology. 2011 Apr;259(1):39-56
pubmed: 21436096
Cancer Drug Resist. 2019 Dec 19;2(4):1018-1031
pubmed: 35582280
Magn Reson Med. 2012 Mar;67(3):769-77
pubmed: 21858862
Phys Med Biol. 2015 Mar 21;60(6):2511-27
pubmed: 25746014
Int J Nanomedicine. 2017 Aug 09;12:5613-5629
pubmed: 28848341
Acta Biomater. 2015 Mar;15:89-101
pubmed: 25575854
Ann Transl Med. 2020 Jun;8(11):673
pubmed: 32617293
Proc Natl Acad Sci U S A. 2017 Nov 28;114(48):E10281-E10290
pubmed: 29133392
Sci Rep. 2018 Dec 7;8(1):17720
pubmed: 30531863
J Biomed Nanotechnol. 2018 Dec 1;14(12):2031-2041
pubmed: 30305211
Sci Rep. 2019 Jan 23;9(1):321
pubmed: 30674905
J Neurooncol. 2022 Apr;157(2):237-247
pubmed: 35267132